Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $311.17 Million |
|---|---|
| Enterprise Value | $272.12 Million |
| Earnings per Share | $0.3 |
| Beta | 1 |
| Outstanding Shares | 81,245,827 |
| P/E Ratio | 10.65 |
|---|---|
| PEG | -6.75 |
| Price to Sales | 0.43 |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | 0.34 |
| Enterprise Value to EBIT | -3.51 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.11 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Aus...